Form 8-K - Current report:
SEC Accession No. 0000950170-22-005040
Filing Date
2022-03-30
Accepted
2022-03-30 16:03:22
Documents
14
Period of Report
2022-03-30
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K bolt-20220330.htm   iXBRL 8-K 52590
2 EX-99.1 bolt-ex99_1.htm EX-99.1 431948
3 GRAPHIC img192637872_0.jpg GRAPHIC 3892
  Complete submission text file 0000950170-22-005040.txt   631477

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bolt-20220330_pre.xml EX-101.PRE 10377
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bolt-20220330_lab.xml EX-101.LAB 14110
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bolt-20220330.xsd EX-101.SCH 2480
8 EXTRACTED XBRL INSTANCE DOCUMENT bolt-20220330_htm.xml XML 4940
Mailing Address 900 CHESAPEAKE DRIVE REDWOOD CITY CA 94063
Business Address 900 CHESAPEAKE DRIVE REDWOOD CITY CA 94063 650-665-9295
Bolt Biotherapeutics, Inc. (Filer) CIK: 0001641281 (see all company filings)

IRS No.: 472804636 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39988 | Film No.: 22786387
SIC: 2834 Pharmaceutical Preparations